6.
  
    Llamusi B, Bargiela A, Fernandez-Costa J, Garcia-Lopez A, Klima R, Feiguin F
    
    . Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model. Dis Model Mech. 2012; 6(1):184-96.
          PMC: 3529350.
    
          DOI: 10.1242/dmm.009563.
    
    
View
   
 
                                          
  7.
  
    Du H, Cline M, Osborne R, Tuttle D, Clark T, Donohue J
    
    . Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol. 2010; 17(2):187-93.
          PMC: 2852634.
    
          DOI: 10.1038/nsmb.1720.
    
    
View
   
 
                                          
  8.
  
    Loro E, Rinaldi F, Malena A, Masiero E, Novelli G, Angelini C
    
    . Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells. Cell Death Differ. 2010; 17(8):1315-24.
    
          DOI: 10.1038/cdd.2010.33.
    
    
View
   
 
                                          
  9.
  
    Lee K, Li M, Manchanda M, Batra R, Charizanis K, Mohan A
    
    . Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol Med. 2013; 5(12):1887-900.
          PMC: 3914532.
    
          DOI: 10.1002/emmm.201303275.
    
    
View
   
 
                                          
  10.
  
    Silvers R, Keller H, Schwalbe H, Hengesbach M
    
    . Differential scanning fluorimetry for monitoring RNA stability. Chembiochem. 2015; 16(7):1109-14.
    
          DOI: 10.1002/cbic.201500046.
    
    
View
   
 
                                          
  11.
  
    Gonzalez A, Konieczny P, Llamusi B, Delgado-Pinar E, Borrell J, Teixido J
    
    . In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models. PLoS One. 2017; 12(6):e0178931.
          PMC: 5459475.
    
          DOI: 10.1371/journal.pone.0178931.
    
    
View
   
 
                                          
  12.
  
    Case D, Cheatham 3rd T, Darden T, Gohlke H, Luo R, Merz Jr K
    
    . The Amber biomolecular simulation programs. J Comput Chem. 2005; 26(16):1668-88.
          PMC: 1989667.
    
          DOI: 10.1002/jcc.20290.
    
    
View
   
 
                                          
  13.
  
    Bargiela A, Sabater-Arcis M, Espinosa-Espinosa J, Zulaica M, de Munain A, Artero R
    
    . Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models. Proc Natl Acad Sci U S A. 2019; 116(50):25203-25213.
          PMC: 6911202.
    
          DOI: 10.1073/pnas.1820297116.
    
    
View
   
 
                                          
  14.
  
    Chen G, Masuda A, Konishi H, Ohkawara B, Ito M, Kinoshita M
    
    . Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy. Sci Rep. 2016; 6:25317.
          PMC: 4850456.
    
          DOI: 10.1038/srep25317.
    
    
View
   
 
                                          
  15.
  
    Ashizawa T, Gagnon C, Groh W, Gutmann L, Johnson N, Meola G
    
    . Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol Clin Pract. 2018; 8(6):507-520.
          PMC: 6294540.
    
          DOI: 10.1212/CPJ.0000000000000531.
    
    
View
   
 
                                          
  16.
  
    Timchenko N, Iakova P, Cai Z, Smith J, Timchenko L
    
    . Molecular basis for impaired muscle differentiation in myotonic dystrophy. Mol Cell Biol. 2001; 21(20):6927-38.
          PMC: 99869.
    
          DOI: 10.1128/MCB.21.20.6927-6938.2001.
    
    
View
   
 
                                          
  17.
  
    Reese H, Shanahan C, Proulx C, Menegatti S
    
    . Peptide science: A "rule model" for new generations of peptidomimetics. Acta Biomater. 2019; 102:35-74.
    
          DOI: 10.1016/j.actbio.2019.10.045.
    
    
View
   
 
                                          
  18.
  
    Garcia-Lopez A, Monferrer L, Garcia-Alcover I, Vicente-Crespo M, Alvarez-Abril M, Artero R
    
    . Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS One. 2008; 3(2):e1595.
          PMC: 2220037.
    
          DOI: 10.1371/journal.pone.0001595.
    
    
View
   
 
                                          
  19.
  
    Cerro-Herreros E, Gonzalez-Martinez I, Moreno-Cervera N, Overby S, Perez-Alonso M, Llamusi B
    
    . Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy. Mol Ther Nucleic Acids. 2020; 21:837-849.
          PMC: 7452101.
    
          DOI: 10.1016/j.omtn.2020.07.021.
    
    
View
   
 
                                          
  20.
  
    Fosgerau K, Hoffmann T
    
    . Peptide therapeutics: current status and future directions. Drug Discov Today. 2014; 20(1):122-8.
    
          DOI: 10.1016/j.drudis.2014.10.003.
    
    
View